Searched for
OTSUKA PHARMACEUTICAL
Lupin launches generic version of kidney disorder treatment drug in USLupin Ltd has launched generic Tolvaptan tablets in the US, after receiving USFDA approval. These tablets, with strengths of 15 mg, 30 mg, ...- Alembic Pharmaceuticals gets USFDA nod for generic antidepressant tabletsAlembic Pharmaceuticals has received final approval from the USFDA for its generic version of Brexpiprazole tablets, used in treating major...
- Alembic Pharma gets USFDA nod to market generic antidepressant drugThe company's product is therapeutically equivalent to Otsuka Pharmaceutical Co's reference listed drug product Rexulti tablets, it added. ...
- Lupin gets tentative nod from USFDA to market generic Brexpiprazole tabletsThe company has received tentative approval from the United States Food and Drug Administration (USFDA) to market generic Brexpiprazole tab...
- New treatment to be made affordable for patients: TB AlliancePretomanid is the third TB drug to have been approved by the USFDA in the last 40 years.
- Hexaware acquires Mobiquity Inc for $182 mnR Srikrishna, CEO, Hexaware Technologies said “Hexaware enters an exciting new phase of growth and capability with the acquisition of Mobiq...
- Nikkei slides to new 15-month low; US worries, stronger yen weighThe broader Topix closed at 1.488.19, down 1.9 per cent.
- Carlyle in talks to invest $100 million in BDR PharmaBDR clocked Rs 550-600 crore in revenue and around Rs 120 crore in FY18 EBITDA.
- Johnson & Johnson , Mylan propose ways to cut TB drugs prices in IndiaJ&J has offered to provide one course of the drug bedaquiline for free if the government buys four courses at $900 (₹58,400) each.
- Otsuka licenses Mylan subsidiary to bring MDR TB drug delamanid to IndiaMDR TB is on the rise in India which, together with China and Russia, accounts for over half of these cases worldwide, according to a recen...
- Otsuka enters deal with Mylan to bring MDR TB drug to IndiaThe Drug Controller General of India has granted Mylan’s subsidiary approval for the drug, according to a release by the company. The drug,...
- Aurobindo gains on USFDA final nod for anti-psychotic tabletsShares of Aurobindo Pharma climbed five per cent today as the company has received final approval from the US health regulator FDA to manuf...
- MNCs deprive India of vital drugs despite getting monopoly rightsJapanese firm Otsuka Pharmaceuticals, Myers-Squibb, Novartis are deferring launch of medicines critical for treatment of serious non-commun...
- Claris Lifesciences completes transfer of Speciality Injectable BusinessShareholders of the company approved the transfer along with all employees, assets and liabilities at a consideration not less than its boo...
- Claris to buy-back 14.49 per cent stake for Rs 231.25 crore"The objective of the buy-back is to return surplus cash to the equity shareholders of the company," Claris said in a filing to the BSE.
- Claris transfers two businesses to Japan JV for Rs 1,050 crClaris will continue to hold a 20 per cent stake in the JV, while Otsuka and Mitsui will hold 60 and 20 per cent in it, respectively, a com...
- Claris Lifesciences gets FIPB nod for Japanese JV, Q1 net down by 29%Ahmedabad-based Claris Lifesciences registered de-growth of 29% in its first quarter ended on 31st March 2013.
- Claris Lifesciences to invest Rs 900 crore on business growth, pre-payment of debtClaris Lifesciences on Thursday said it will invest Rs 900 crore, which it expects to receive as part of divestment of 80 per cent stake in...
- Claris Lifesciences inks JV with Japanese drug maker Otsuka Pharma & Mitsui for Indian marketAhmedabad-based Claris Lifesciences Limited, India executed agreements for a Joint Venture with two Japan-based drug makers Otsuka Pharmace...
- Otsuka commences unit's production in RajasthanOtsuka Chemical India (OCIL), a wholly-owned subsidiary of Japanese company Ostuka Chemical Co. Ltd, on Friday announced commencement of pr...
Load More
